UNSPSC 51172169: Drofenine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H31NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MVB31OPW05, chemically known as cyclohexaneacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as drofenine hydrochloride, which bears US NIH Compound Identifier 92806. European Medicines Agency schedules Drofenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01838MIG.

Most nations, for tariff and trade purposes, schedule drofenine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DROFENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.CL.

UNSPSC 51172169 Drofenine hydrochloride is a Commodity code under which state and local governments procure pharmaceutical products and drug-testing services, though recent solicitations show activity concentrated in specimen collection and testing programs rather than the specific active pharmaceutical ingredient alone. The issuing bodies soliciting under this code span county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state and local government facilities. Collin County Community Supervision and Corrections Department posted an RFP in July 2026 for offender specimen collection and drug testing services, with an estimated contract value of $600,000 and a response deadline of July 23, 2026, encompassing staffing of two collection sites, immunoassay screening with confirmatory testing by LC/MS/MS or GC/MS, electronic result reporting, and alternative testing methodologies including oral fluid and hair testing. The Texas Health and Human Services Commission issued an RFI in April 2026 on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions, seeking vendor capability information on direct contracting with pharmaceutical manufacturers to improve prescription fulfillment and cost management outside traditional pharmacy benefit manager channels.

Recent activity spans Texas and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed to state and local government facilities across participating jurisdictions including Oregon, with proposals due March 26, 2026. The Collin County opportunity prioritizes vendor understanding of offender testing protocols (30 points), firm qualifications and client references (40 combined points), and cost competitiveness (30 points), with awards anticipated August 10, 2026 and contract commencement September 1, 2026 for an initial two-year term with three optional one-year renewals. The MMCAP RFP weights price competitiveness at 75 percent of evaluation, requires compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, mandates relationships with at least two of three authorized wholesalers, and extends through June 30, 2028 with optional MMCAP extensions. Neither the Collin County nor MMCAP solicitations identify specific set-aside or disadvantaged-enterprise restrictions based on available documentation.